SHAKEN, NOT STRUCK: UNDERSTANDING INERTIAL BRAIN INJURY

Most people picture a brain injury as the result of a direct blow — head meets object, object meets head. But some of the most consequential neurological injuries involve no impact at all. These are called inertial brain injuries, and understanding the physics behind them helps explain why a person can walk away from a car accident, a fall, or a sports collision looking perfectly fine, only to struggle with memory, attention, mood, etc. weeks later.

The brain is a soft, gel-like organ suspended in cerebrospinal fluid inside a rigid skull. When the head experiences rapid acceleration or deceleration — as in a whiplash-type car crash, a fall, or a violent shake — the skull and brain do not move in perfect unison. The skull stops or changes direction faster than the brain tissue inside it. This mismatch creates rotational and shear forces, not just linear ones. Rotational acceleration is particularly damaging because brain tissue tolerates straight-line, or translational, forces reasonably well but is far more vulnerable to twisting forces. The brain's various structures — gray matter, white matter, blood vessels — have different densities and different rates of deceleration, so they lag behind one another during the injury event. That differential movement is the mechanical heart of an inertial injury, and it can happen with no external impact to the head.

At the microscopic level, this differential movement stretches and twists axons, the long, thread-like projections that neurons use to communicate with one another. It helps to think of the brain's white matter as something like a thick bundle of wires running through the walls of a house. Each wire, or axon, has to stay intact along its entire length to carry a signal properly. Bend or jostle the bundle gently and the wires flex and recover. But twist the whole bundle sharply and unevenly, the way rotational forces do inside the skull, and individual wires inside it can stretch past their limit, fray, or lose their internal integrity, even though the outer casing of the bundle looks completely undamaged from the outside. That is essentially what happens with axonal shearing: the axon's internal transport system, its own version of the wire's conductive core, gets disrupted, even when the brain as a whole looks intact on the surface. When axons are stretched beyond their elastic capacity, the injury is called diffuse axonal injury. In more severe cases, the axon can swell, disconnect, and undergo a slower secondary degeneration over hours to days, meaning the full extent of injury isn't always apparent immediately. Because axons run throughout the brain, much like wiring runs throughout every room of a house, diffuse axonal injury tends to be widespread rather than localized, which is why symptoms can be broad, affecting attention, processing speed, memory retrieval, and executive functioning simultaneously rather than producing a single, clean deficit. The areas most frequently affected include the junctions between gray and white matter, the corpus callosum, and the brainstem — regions where tissue of different density meet and shear stress concentrates, similar to where a wire bundle bends sharply around a corner and takes on the most strain.

The mechanical damage to axons also sets off a cascade of chemical changes inside the brain, sometimes called the neurometabolic cascade of injury. Stretched and disrupted cell membranes cause ions to flow abnormally across them, triggering an uncontrolled release of the neurotransmitter glutamate. Glutamate is normally essential for healthy brain signaling, but in excess it overactivates neighboring neurons, a process called excitotoxicity, which places further stress on cells already weakened by the mechanical injury. This ionic disruption forces brain cells to work harder to restore their normal balance, sharply increasing their demand for glucose and energy at precisely the time when blood flow to the injured area is often reduced. The result is a temporary mismatch between how much energy the brain needs and how much it can actually deliver, which can last for days to weeks after the initial injury. This chemical and metabolic disturbance, layered on top of the structural axonal damage, is thought to contribute to the fatigue, difficulty concentrating, and sensitivity to cognitive or physical exertion that many patients describe well after the injury itself has technically "healed."

This is where inertial injury becomes clinically tricky. Conventional CT and standard MRI are often normal in cases of diffuse axonal injury, particularly in mild-to-moderate cases, because the damage occurs at a microscopic, axonal level rather than as a visible mass or bleed. More sensitive sequences can help. Susceptibility-weighted imaging and gradient echo MRI are more sensitive to the microhemorrhages that sometimes accompany axonal shearing, while diffusion tensor imaging, largely a research and specialized clinical tool, can detect disruptions in white matter tract integrity that standard MRI misses. Even so, a normal scan does not rule out a real injury. This gap between imaging and lived symptoms is one of the most important, and most misunderstood, aspects of inertial brain injury, and it's a frequent point of dispute in both clinical and legal settings.

Because structural imaging can under-detect diffuse axonal injury, neuropsychiatric testing plays a central role in characterizing its functional impact. Standardized cognitive testing can identify patterns consistent with diffuse, multi-domain involvement, including slowed processing speed, reduced sustained attention and working memory, difficulty with verbal or visual memory retrieval and encoding, and executive dysfunction affecting planning, cognitive flexibility, and inhibition. A thorough evaluation also incorporates performance validity testing to ensure that results reflect genuine effort and are interpretable, along with a review of pre-injury baseline functioning, mood, sleep, and other factors that can influence cognitive performance. No single test result proves an inertial brain injury in isolation; the value comes from the overall pattern, considered alongside the mechanism of injury, imaging, and clinical history.

Inertial brain injury sits at an interesting intersection of physics, cellular biology, and behavior. The mechanism, differential movement of brain tissue relative to the skull, is well established in the biomechanics literature. What remains genuinely difficult is translating that mechanism into individual diagnosis and prognosis, given the limitations of current imaging and the wide variability in how people recover. 

Good clinical practice acknowledges both: the injury is real and mechanistically well understood, and the tools we have to measure it in any one person are still imperfect. That combination is exactly why a multifactorial approach is crucial; imaging where appropriate, careful history-taking, and formal neuropsychiatric testing remain the most reliable way to understand what has actually happened inside a person's head.

MENOPAUSE AND SURGICAL MENOPAUSE: THE NEUROBIOLOGY OF HORMONES

When we think about injuries, we often focus on the visible consequences. We think about broken bones, open wounds, surgeries, and physical rehabilitation. We do not often think about the endocrine system, yet it is one of the body's most powerful regulators of overall health and brain function. The endocrine system is a network of hormone-producing glands that influences nearly every organ system, including the central nervous system.

For some women who sustain severe pelvic injuries requiring bilateral oophorectomy (surgical removal of both ovaries), one of the most significant consequences is not simply the loss of reproductive function, but the abrupt disruption of the endocrine system. As ovarian hormone production ceases, many women begin to describe difficulty concentrating, forgetting conversations, searching for words, mental fatigue, slower thinking, and feeling as though they are no longer thinking as clearly as they once did.

For decades, medicine has taught us an important lesson. Women's symptoms have not always been fully recognized or adequately explained. Historically, women reporting pain, fatigue, or neurocognitive concerns were more likely to have their symptoms attributed to stress, anxiety, or emotional distress rather than underlying biological processes. Although medicine has made tremendous progress, research continues to demonstrate that women experience delays in diagnosis across numerous medical conditions and that biological differences unique to women have often been underrepresented in medical research. These historical lessons remind us to remain thoughtful, objective, and scientifically curious rather than dismissive.

This perspective becomes particularly important when considering menopause and, more specifically, surgical menopause.

Menopause is one of the most significant neuroendocrine transitions in a woman's life. While it is commonly associated with reproductive aging, its effects extend well beyond the reproductive system. As ovarian estrogen and progesterone production gradually declines, the brain undergoes complex neurochemical adaptations that influence neurotransmitter systems involved in neurocognition, mood, sleep, and emotional regulation. For many women, this transition is accompanied by changes in neurocognitive efficiency, sleep quality, vasomotor symptoms, fatigue, and mood that can meaningfully affect daily functioning and quality of life.

Although these symptoms are biologically mediated and represent a normal consequence of changing endocrine physiology, they are too often minimized or dismissed as simply "part of being a woman" or "just part of life." Normal does not mean insignificant.

Recognizing the neurobiology underlying menopause not only validates these experiences, but also creates opportunities for thoughtful evaluation, appropriate treatment, and ultimately, improved outcomes.

If the gradual hormonal transition of natural menopause can meaningfully influence brain function, it follows that an abrupt interruption of ovarian hormone production may have even greater neurobiological implications.

Natural menopause typically unfolds over several years, allowing the brain and body time to gradually adapt to changing hormone levels and the accompanying neurochemical changes. Symptoms may still be significant, but the central nervous system has an opportunity to recalibrate as hormone levels evolve. Surgical menopause is fundamentally different. Following bilateral oophorectomy, ovarian production of estrogen and progesterone declines abruptly, producing an immediate neuroendocrine shift. Rather than adapting over time, the brain is suddenly required to function within an entirely different hormonal environment, often while the individual is simultaneously recovering from major surgery, managing pain, and coping with the emotional and practical consequences of a workplace injury.

Estrogen is far more than a reproductive hormone. It is one of the brain's most influential neuromodulators. Estrogen receptors are widely distributed throughout the hippocampus, prefrontal cortex, amygdala, and other brain regions responsible for learning, memory, attention, executive functioning, and emotional regulation. Through these interconnected neural networks, estrogen helps regulate neurotransmitters essential for healthy neurocognitive functioning.

Estrogen supports acetylcholine, a neurotransmitter critical for attention, learning, and memory formation. It modulates dopamine within the prefrontal cortex, supporting working memory, cognitive flexibility, executive functioning, and mental efficiency. Estrogen also influences serotonin and GABA, neurotransmitters involved in mood regulation, sleep architecture, anxiety modulation, and overall neurocognitive performance. Although estrogen has received the greatest scientific attention, progesterone also contributes to healthy brain function through its effects on GABAergic neurotransmission, emotional regulation, and sleep. Together, these hormones help maintain the delicate neurochemical balance necessary for efficient brain function.

Beyond neurotransmission, estrogen supports synaptic plasticity, promotes dendritic spine formation within the hippocampus, and facilitates the brain's remarkable capacity to adapt, learn, and form new memories throughout adulthood. When estrogen declines abruptly, these highly integrated neural networks become less efficient. Women may experience slower processing speed, increased distractibility, reduced mental endurance, impaired learning efficiency, forgetfulness, word-finding difficulties, and reduced cognitive flexibility. Importantly, these symptoms do not necessarily indicate structural brain injury. More often, they reflect functional changes in brain performance resulting from abrupt neuroendocrine disruption.

From a medical-legal perspective, this distinction is critical. If a pelvic injury results in bilateral oophorectomy and subsequent surgical menopause, the endocrine consequences become an essential component of the differential diagnosis. Neurocognitive symptoms should not automatically be attributed solely to psychological distress, nor should they automatically be presumed to represent traumatic brain injury. Instead, they should be evaluated within the broader context of endocrine physiology, neuroscience, sleep, chronic pain, medications, psychiatric functioning, and other medical conditions capable of influencing neurocognition.

This is where a comprehensive neurocognitive evaluation becomes invaluable.

Objective neurocognitive testing allows us to move beyond subjective symptom reports and identify specific neurocognitive strengths and weaknesses. Equally important, it helps distinguish subjective cognitive complaints from objectively measurable neurocognitive dysfunction. Careful assessment can identify changes in attention, learning, memory, processing speed, executive functioning, language, and emotional functioning while simultaneously considering the contribution of hormonal changes, sleep disturbance, chronic pain, medications, psychiatric symptoms, and neurological injury. The goal is not simply to determine whether neurocognitive symptoms exist, but to understand the mechanisms contributing to those symptoms. Understanding the mechanism is what allows us to develop meaningful, individualized treatment recommendations.

Many neurocognitive changes associated with surgical menopause may improve when contributing factors are recognized and appropriately addressed. Optimizing sleep, effectively treating mood symptoms, managing chronic pain, addressing endocrine health when appropriate, and implementing evidence-based cognitive rehabilitation strategies may all contribute to improved day-to-day functioning. Hope begins with understanding. Once the underlying mechanisms are identified, patients and treating providers can focus on interventions that target the factors most likely to improve function and quality of life.

As physicians, our responsibility is to remain objective, scientifically grounded, and mindful of our own cognitive biases. Every patient deserves to have their symptoms evaluated through the lens of current medical evidence rather than historical assumptions. By integrating objective neurocognitive testing with medical history, endocrine physiology, and neuroscience, we are better equipped to identify the underlying mechanisms contributing to neurocognitive change.

Ultimately, objective neurocognitive testing does far more than strengthen a medical-legal opinion. It provides clarity. It validates what is measurable. It identifies what is potentially treatable. Most importantly, it offers patients something they often need most: hope.

The brain does not function independently of the endocrine system. When hormones change, neurotransmitters change. When neurotransmitters change, neurocognition can change. Understanding these relationships allows us to replace assumptions with science, uncertainty with clarity, and ultimately, create a more meaningful path toward recovery.

THE DIFFERENCE BETWEEN FEELING IMPAIRED AND BEING IMPAIRED

One of the most common concerns I hear during a neuropsychiatric evaluation is, "My memory isn't what it used to be," or "I just don't feel as sharp as I was before." Individuals may report difficulty concentrating, forgetting conversations, losing their train of thought, struggling to multitask, or feeling mentally fatigued throughout the day. These concerns are often frustrating, can affect confidence, and understandably raise questions about whether a cognitive impairment is present.

While these symptoms are important and should never be dismissed, one of the most common misconceptions is that cognitive symptoms and cognitive impairment are the same thing.

Symptoms tell us what an individual is experiencing. Cognitive impairment, on the other hand, refers to objective deficits that can be identified through clinical evaluation and standardized testing. The distinction is important because many factors can influence how a person feels cognitively, and those factors do not always reflect an underlying neurological injury or measurable cognitive decline.

For example, individuals coping with chronic pain often report difficulties with concentration and memory. Poor sleep can significantly affect attention, processing speed, and learning. Anxiety, depression, emotional stress, and even certain medications may contribute to a sense of mental fogginess or forgetfulness. These experiences are very real and can have a meaningful impact on daily functioning. However, the presence of symptoms alone does not answer the question that is often most relevant from both a clinical and medical-legal perspective: Is there objective evidence of cognitive impairment?

Cognitive testing provides an objective assessment of an individual's abilities across multiple areas of functioning, including attention, concentration, processing speed, learning, memory, executive functioning, language, and problem-solving. Rather than relying solely on self-report, testing allows us to evaluate what an individual is actually capable of doing under standardized conditions.

Perhaps even more importantly, cognitive testing helps us determine whether there has been a meaningful change from baseline functioning.

When evaluating allegations of cognitive decline, the question is often not simply whether someone demonstrates weaknesses on testing. The more important question is whether those findings represent a decline from the person's expected level of functioning before the injury or event in question.

Every individual enters an evaluation with a unique background. Educational level, occupational history, intellectual abilities, language proficiency, and lifelong cognitive strengths all influence performance. A test score that may be entirely expected for one individual could represent a significant decline for another.

For example, a successful executive, engineer, or business owner may continue to score within average ranges on cognitive testing yet still demonstrate evidence of decline when compared to their estimated premorbid abilities. Conversely, an individual with longstanding educational challenges may obtain lower scores that are entirely consistent with their historical level of functioning and unrelated to a recent injury.

For this reason, comprehensive neuropsychiatric evaluations do not focus solely on test scores in isolation. We also evaluate educational attainment, occupational achievements, medical history, academic performance, language background, and other factors that help estimate premorbid functioning. Specialized measures within the testing battery also assist in estimating an individual's expected baseline level of cognitive functioning.

This process allows us to place current performance into meaningful context. Rather than simply asking, "How did this person perform today?" we are asking, "How does this person perform today compared to what we would reasonably expect based on their history, background and estimated premorbid functioning?"

In medical-legal cases, questions regarding causation, apportionment, disability, and functional limitations frequently depend upon whether objective evidence supports a change in functioning. Symptoms alone cannot answer that question. Similarly, a single test score rarely tells the whole story. The value of cognitive testing lies in its ability to integrate objective findings with an individual's history and provide a more complete understanding of their functioning.

Another benefit of cognitive testing is that it helps identify strengths as well as weaknesses. Not every evaluation reveals impairment. In many cases, individuals discover that their cognitive abilities remain intact despite concerns about memory or concentration. This can be reassuring and may help direct attention toward other treatable contributors such as sleep disruption, chronic pain, emotional distress, or medication effects. In other cases, testing may identify genuine deficits that warrant treatment, accommodations, or further intervention.

Ultimately, an evaluation is not simply about determining whether symptoms exist. It is about understanding what those symptoms mean. By combining clinical history, behavioral observations, objective testing, and estimates of premorbid functioning, we can determine whether there is evidence of true cognitive impairment and, perhaps most importantly, whether there has been a meaningful change from baseline.

Patients' reported symptoms provide an important starting point. Cognitive testing helps us objectively assess capacity, quantify functioning, and place those symptoms into context. Together, they allow for more accurate diagnoses, more targeted treatment recommendations, and more reliable medical-legal opinions.